Hostname: page-component-7c8c6479df-8mjnm Total loading time: 0 Render date: 2024-03-28T18:39:00.070Z Has data issue: false hasContentIssue false

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

Published online by Cambridge University Press:  02 January 2018

G. C. Dunbar*
Affiliation:
CNS Therapeutic Unit, Clinical Research and Development, SmithKline Beecham Pharmaceuticals
J. B. Cohn
Affiliation:
Psychopharmacology Research Institute, Long Beach
L. F. Fabre
Affiliation:
Research Testing, Inc.
J. P. Feighner
Affiliation:
Feighner Research Institute
R. R. Fieve
Affiliation:
The Foundation for Depression and Manic Depression, Inc.
J. Mendels
Affiliation:
Philadelphia Medical Institute
R. K. Shrivastava
Affiliation:
Eastside Comprehensive Medical Services, New York
*
47–49 London Road, Reigate, Surrey RH2 9YF

Abstract

To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, both the 240 paroxetine-treated and the 237 imipramine-treated patients were significantly different from the 240 placebo-treated patients, but no different from each other. Side-effects with paroxetine were less likely to lead to drop-out than with imipramine. Paroxetine had a possible earlier antidepressant effect than imipramine, and a possible earlier beneficial effect on anxiety symptoms associated with depression.

Type
Papers
Copyright
Copyright © 1991 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1960) Diagnostic and Statistical Manual of Mental Disorders (3rd edn). Washington DC: APA.Google Scholar
Cooper, S. M., Jackson, D., London, J. M., et al (1989) The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam or alcohol. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 5355.Google Scholar
Covi, L., Rickels, K., Lipman, O. S., et al (1981) Effects of psychotropic agents on primary depression. Psychopharmacology Bulletin, 17, 100101.Google Scholar
Doogan, D. P. & Caillard, V. (1988) Sertraline: a new antidepressant. Journal of Clinical Psychiatry, 49 (suppl. 8), 4651.Google Scholar
Feighner, J. P. & Boyer, W. F. (1989) Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 125129.Google Scholar
Food and Drug Administration (1989) ‘COSTART’ Coding Symbols for Thesaurus of Adverse Reaction Terms (3rd edn). Rockville, Md: FDA.Google Scholar
Haddock, R. E., Johnson, A. M., Langley, P. F., et al (1989) Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 2426.CrossRefGoogle Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.Google Scholar
Herman, J. B., Brotman, A. W., Pollack, M. H., et al (1990) Fluoxetine-induced sexual dysfunction. Journal of Clinical Psychiatry, 51, 2527.Google Scholar
Johnson, A. (1989) An overview of the animal pharmacology of paroxetine. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 1420.Google Scholar
Kaye, C. M., Haddock, R. E., Langley, P. F., et al (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 6075.Google Scholar
Marsden, C. A. (1987) Changes in human whole blood 5-HT and platelet 5-HT during treatment with paroxetine, a selective 5-HT uptake inhibitor. Journal of Psychopharmacology, 1, 244250.Google Scholar
Mas, M., Zahrandisk, M. A., Martino, V., et al (1985) Stimulation of spinal serotonergic receptors stimulates seminal emission and suppresses penile erectile reflexes. Brain Research, 342, 128134.CrossRefGoogle ScholarPubMed
McClelland, G. R. & Raptopoulus, P. (1984) EEG and blood levels of the potential antidepressant paroxetine after a single oral dose to normal volunteers. Psychopharmacology, 83, 327329.CrossRefGoogle ScholarPubMed
McClelland, G. R. & Raptopoulus, P. Jackson, D. (1989) The effect of paroxetine on the quantitative EEG. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 5052.CrossRefGoogle Scholar
Montgomery, S. A. & Asberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382389.CrossRefGoogle ScholarPubMed
Okuyama, S., Shimamura, H., Hashimoto, S., et al (1987) Relation between yawning behaviour and central serotonergic neuronal system in rats. Archives of Pharmacology, 335, 667672.CrossRefGoogle ScholarPubMed
Raptopoulus, P., McClelland, G. R. & Jackson, D. (1989) The clinical pharmacology of paroxetine in healthy subjects. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 4648.Google Scholar
Raskin, A., Schulterbrandt, J., Rectig, N., et al (1969) Replication of factors of psychopathology in interview, ward behaviour, and self report ratings of hospitalised depressives. Journal of Nervous and Mental Disease, 148, 8798.Google Scholar
Renji, L. (1986) The effect of selective 5-HT uptake inhibitors on 5-methoxy-N, N dimethyl tryptamine-induced ejaculation in the rat. British Journal of Pharmacology, 87, 639648.Google Scholar
Thomas, D. R., Nelson, D. R. & Johnson, A. M. (1987) Biochemical effect of the antidepressant paroxetine, a specific 5-HT (hydroxytryptamine) uptake inhibitor. Psychopharmacology, 93, 193200.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.